 |
| John Hubbard |
Clinical trial service provider BioClinica is stretching out in the biopharma hotbed of Research Triangle Park, NC, opening a new operation to play a bigger role in drug development in the region.
The company, headquartered in Pennsylvania, cut the ribbon on a Durham outpost with space for 40 employees, cozying up to the many study sponsors and CROs in the area in hopes of expanding the use of its eClinical products. The company specializes in providing imaging services, data analytics and risk-based monitoring technology around the world, and homing in on the growing RTP research community was a natural next step, CEO John Hubbard said.
Key to the new operation is a sizable classroom space BioClinica plans to use for hands-on training and product demonstration, the CEO said, which the company will use to expose potential partners to its products.
"This gives our customers and staff a place to collaborate face-to-face and a demo environment to try out our eClinical technologies," Hubbard said in a statement.
Hubbard, who took the reins in January, is leading an evolving company just months removed from its last merger. In June, BioClinica acquired Blueprint Clinical and its cloud-based tool for tracking and scoring clinical trial sites. That agreement came on the heels of a 2014 buyout of CCBR-Synarc that stretched BioClinica's focus to include medical imaging and specialty services for clinical trials.
Private equity firm JLL Partners bought BioClinica for $123 million in 2013 and subsequently merged the company with CoreLab, owned by Ampersand Capital Partners, which kept its stake in the combined outfit.
The privately held company said its eClinical sales jumped 51% last year, reflecting a spike in Big Pharma's adoption of new trial technologies. The company reported 25 new partnerships last year and now boasts a client roster above 150, and its string of buyouts have grown its payroll to more than 1,300 people around the world.
- read the statement